BSE Live
Nov 11, 16:01Prev. Close
928.50
Open Price
935.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 11, 15:49Prev. Close
929.20
Open Price
936.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
925.30 (196)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 12.47 | 12.33 | 99.64 | 12.14 | 19.50 | |
| Diluted EPS (Rs.) | 12.47 | 12.32 | 99.61 | 12.12 | 19.38 | |
| Cash EPS (Rs.) | 22.70 | 21.59 | 108.31 | 19.97 | 29.87 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 354.51 | 363.69 | 353.28 | 361.49 | 350.93 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 354.51 | 363.69 | 353.28 | 361.49 | 350.93 | |
| Dividend / Share(Rs.) | 14.00 | 3.00 | 2.00 | 4.50 | 4.00 | |
| Revenue from Operations/Share (Rs.) | 186.92 | 171.69 | 164.20 | 154.53 | 246.62 | |
| PBDIT/Share (Rs.) | 34.63 | 28.33 | 39.47 | 38.00 | 47.35 | |
| PBIT/Share (Rs.) | 24.40 | 19.06 | 30.78 | 30.17 | 35.50 | |
| PBT/Share (Rs.) | 16.96 | 12.62 | 18.34 | 20.42 | 21.19 | |
| Net Profit/Share (Rs.) | 12.47 | 12.32 | 99.62 | 12.14 | 18.03 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 18.52 | 16.49 | 24.03 | 24.58 | 19.19 | |
| PBIT Margin (%) | 13.05 | 11.09 | 18.74 | 19.52 | 14.39 | |
| PBT Margin (%) | 9.07 | 7.35 | 11.16 | 13.21 | 8.59 | |
| Net Profit Margin (%) | 6.67 | 7.17 | 60.66 | 7.85 | 7.30 | |
| Return on Networth / Equity (%) | 3.51 | 3.38 | 28.19 | 3.35 | 5.13 | |
| Return on Capital Employed (%) | 6.75 | 5.21 | 8.65 | 6.66 | 3.95 | |
| Return on Assets (%) | 2.38 | 2.36 | 20.80 | 1.98 | 3.00 | |
| Total Debt/Equity (X) | 0.27 | 0.25 | 0.19 | 0.44 | 0.45 | |
| Asset Turnover Ratio (%) | 35.80 | 32.97 | 34.29 | 25.20 | 41.07 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.01 | 1.20 | 1.36 | 1.80 | 2.06 | |
| Quick Ratio (X) | 0.70 | 0.86 | 1.11 | 1.51 | 1.77 | |
| Inventory Turnover Ratio (X) | 3.76 | 3.25 | 5.45 | 3.37 | 5.81 | |
| Dividend Payout Ratio (NP) (%) | 139.93 | 16.22 | 5.36 | 39.82 | 26.36 | |
| Dividend Payout Ratio (CP) (%) | 76.87 | 9.26 | 4.93 | 24.21 | 15.90 | |
| Earnings Retention Ratio (%) | -39.93 | 83.78 | 94.64 | 60.18 | 73.64 | |
| Cash Earnings Retention Ratio (%) | 23.13 | 90.74 | 95.07 | 75.79 | 84.10 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 3,632.94 | 4,851.72 | 6,539.54 | 11,130.34 | 11,056.08 | |
| EV/Net Operating Revenue (X) | 2.17 | 3.16 | 4.45 | 8.05 | 5.02 | |
| EV/EBITDA (X) | 11.71 | 19.13 | 18.51 | 32.76 | 26.14 | |
| MarketCap/Net Operating Revenue (X) | 1.73 | 2.75 | 4.09 | 7.10 | 4.41 | |
| Retention Ratios (%) | -39.93 | 83.77 | 94.63 | 60.17 | 73.63 | |
| Price/BV (X) | 0.91 | 1.30 | 1.90 | 3.03 | 3.10 | |
| Price/Net Operating Revenue | 1.73 | 2.75 | 4.09 | 7.10 | 4.41 | |
| Earnings Yield | 0.04 | 0.03 | 0.15 | 0.01 | 0.02 |
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
09.09.2025
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
29.07.2025
Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016